ABL1 and neoplasm: Other factors that may modify the disease course and outcome in patients with RCSD1-ABL1 fusion are associated secondary genetic changes, including mutations and deletions of the IKZF1 gene. IKZF codes for a DNA-binding protein Ikaros which displays crucial tumor suppressor functions in the hematopoietic system.